Signal from the log
Trimmune
Biotech
Coentreprise entre HCW Biologics et WY Biotech, qui développe des immunothérapies issues de la plateforme TRBC de HCW Biologics, dont un candidat préclinique en oncologie. Le premier tour est bouclé et ses deux fonds sont nommés, mais son montant n'a pas été communiqué : seuls les 3,5 M$ de licence versés à HCW Biologics le sont.
Spotted Amount read from the headline
Announced on , logged by the watch of 12 August 2026.
- Operation
- Funding round
- Sector
- Biotech
What the log says
Editorial note, in French
Repérée par la collecte. Personne ne l'a encore instruite.
The investors
Led by CITIC Medical Fund , TigerYeah Capital Fund
What is missing before publishing
- No public amount. A missing amount is never estimated or inferred from a filing.
- The stage of the round is not disclosed. A letter is never inferred from an amount or a track record.
Provenance
Source longevity
Logged on 12 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification The fields shown come from an automatic reading of the source headline. They have not yet been checked against the press release and should not be quoted as verified.
What this status means
Spotted The collection saw this operation and logged it. Nobody has processed it yet, so what is shown is still an automatic reading of the source headline.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.